• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Hedge funds betting on J&J after Actelion remains silent on takeover bid

December 2, 2016 By Sarah Faulkner

Hedge funds betting on J&J after Actelion remains silent on takeover bidDespite reports this week that Actelion Pharmaceuticals (VTX:ATLN) rejected Johnson & Johson‘s (NYSE:JNJ) 2nd takeover bid, hedge funds are piling into the Swiss biotech firm, encouraged by Actelion’s silence on the matter.

The 2 companies have been engaged in informal talks for 2 months, according to Reuters, and the latest offer was pegged at 250 Swiss francs per share. J&J’s $27 billion bid for Actelion is tempting to shareholders, who would rather have the cash now than wait and bet on Actelion CEO Jean-Paul Clozel’s risky pipeline for therapeutics of rare diseases.

Earlier in the week, streetinsider.com reported that Clozel decided to reject J&J’s offer, which sent the firm’s shares down -6% in afternoon trading. But Actelion has not made any formal statement since the companies confirmed the initial talks and investors see that as a promising sign that J&J’s approach will result in an outright takeover.

In the past, Clozel has asserted that the company should remain independent. In 2011, he rallied shareholders against an investor’s campaign to sell the firm and then in 2015 rejected a takeover interest from drugmaker Shire. Clozel holds 5% in the company he co-founded with his wife, Martine Clozel, who also owns an undisclosed stake.

Clozel will have some explaining to do to shareholders if he rejects J&J’s deal, fund managers told Reuters. But, it appears they believe this deal could be the one that the CEO finally accepts. “We don’t think Clozel is going to fight,” an anonymous hedge fund manager told the news outlet.

Actelion shares soared on Friday after news of the initial offer broke, up 19% to a peak of 187.70 Swiss francs, which put the company at a value of $20 billion. Today, ATLN shares were trading at $204.00 in mid-morning activity, up 4.4%.

Filed Under: Mergers & Acquisitions, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson

IN CASE YOU MISSED IT

  • Tandem Diabetes Care delivers 1 million insulin boluses using t:connect mobile app
  • Nuvo, Sheba Medical Center develop AI-powered gestational diabetes management platform
  • Verily’s Onduo, Sword Health collaborate on virtual diabetes care
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS